The role of Tumour Necrosis Factor in neuroinflammation associated with Parkinson’s disease and targeted therapies
Abstract
Neurodegenerative disorders Parkinson's disease is a progressive neurodegenerative disorder associated with neuroinflammatory responses that lead to the neurodegeneration of the dopaminergic neurons. These neuroinflammatory mechanisms involve various cytokines produced by the activated glial cells. Tumour Necrosis factor α (TNF α) is one of the major mediators of the neuroinflammation associated with neurodegeneration. TNF α has a dual role of neuroprotection and neurotoxicity in the brain. The effective pathways of TNF involve various signalling pathways transduced by the receptors TNFR1 and TNFR2. Effective therapeutic strategies have been produced targeting the neurotoxic behaviour of the Tumour Necrosis Factor and the associated neurodegeneration which includes the use of Dominant Negative Tumour Necrosis Factor (DN-TNF) inhibitors like XENP 345 and XPro®1595 and peroxisome proliferator receptor gamma (PPAR-γ) agonists.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Bioactive molecules such as phenolic compounds, flavonoids and non-flavonoids, carotenoids, and others can exert neuroprotective effects by suppressing activation of microglia that modulates inflammatory processes in the CNS.
“Reports show that bioactive molecules such as phenolic compounds, flavonoids and non-flavonoids, carotenoids, and others can exert neuroprotective effects by suppressing the activation of the microglia that modulates inflammatory processes in the CNS [119,157].”
From Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation (2022) · cites this paper as [119]
Cites
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920 · see citing works
Mechanisms underlying inflammation in neurodegeneration
Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580 · see citing works
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990 · see citing works
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
Kwon, H. S., & Koh, S.-H. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00221-2 · Cited by 2,595 · see citing works
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895 · see citing works
Genetics of Parkinson's DiseasePreprint
Klein, C., & Westenberger, A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008888 · Cited by 1,370 · see citing works
Oxidative Pathways for Catecholamines in the Genesis of Neuromelanin and Cytotoxic Quinones
GRAHAM, D. G. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13535-9 · Cited by 1,126 · see citing works
A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci
Chang, D., Nalls, M. A., Hallgrímsdóttir, I. B., Hunkapiller, J., van der Brug, M., Cai, F., International Parkinson's Disease Genomics Consortium, 23andMe Research Team, Kerchner, G. A., Ayalon, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3955 · Cited by 1,112 · see citing works
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045 · see citing works
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859 · see citing works
Parkinson’s Disease in Women and Men: What’s the Difference?
Cerri, S., Mus, L., & Blandini, F. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191683 · Cited by 806 · see citing works
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779 · see citing works
Duty, S., & Jenner, P. G. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 758 · see citing works
Tumor necrosis factor alpha: A link between neuroinflammation and excitotoxicity
Olmos, G., & Lladó, J. (2014) · Mediators of Inflammation · doi:10.1155/2014/861231 · Cited by 730 · see citing works
Hartmann, A., Hunot, S., Michel, P. P., Muriel, M., Vyas, S., Faucheux, B. A., Prigent, A., Turmel, H., Srinivasan, A. N., Ruberg, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040556597 · Cited by 717 · see citing works
DeMaagd, G. A., & Philip, A. (2015) · PubMed Central · Cited by 571 · see citing works
Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors
Emamzadeh, F. N., & Surguchov, A. P. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00612 · Cited by 570 · see citing works
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Cacabelos, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030551 · Cited by 559 · see citing works
Changes in cytokines and neurotrophins in Parkinson’s disease
Nagatsu, T., Mogi, M., Ichinose, H., & Togari, A. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_19 · Cited by 507 · see citing works
Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
Hald, A., & Lotharius, J. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.01.013 · Cited by 506 · see citing works
BDNF as a Promising Therapeutic Agent in Parkinson’s Disease
Palasz, E., Wysocka, A., Gasiorowska, A., Chalimoniuk, M., Niewiadomski, W., & Niewiadomska, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031170 · Cited by 504 · see citing works
Parkinson's Disease and the Environment
Ball, N., Teo, W., Chandra, S., & Chapman, J. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00218 · Cited by 481 · see citing works
An update on the diagnosis and treatment of Parkinson disease
Rizek, P., Kumar, N., & Jog, M. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.151179 · Cited by 455 · see citing works
Chia, R., Sabir, M. S., Bandres-Ciga, S., Saez-Atienzar, S., Reynolds, R. H., Gustavsson, E., Walton, R. L., Ahmed, S., Viollet, C., Ding, J., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00785-3 · Cited by 438 · see citing works
Major Shifts in Glial Regional Identity Are a Transcriptional Hallmark of Human Brain Aging
Soreq, L., Rose, J., Soreq, E., Hardy, J., Trabzuni, D., Cookson, M. R., Smith, C., Ryten, M., Patani, R., & Ule, J. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.011 · Cited by 419 · see citing works
Microglia and astrocyte dysfunction in parkinson's disease
Kam, T., Hinkle, J. T., Dawson, T. M., & Dawson, V. L. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105028 · Cited by 399 · see citing works
Peter, I., Dubinsky, M., Bressman, S., Park, A., Lu, C., Chen, N., & Wang, A. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0605 · Cited by 386 · see citing works
Glutamate-induced excitotoxicity in Parkinson's disease: The role of glial cells
Iovino, L., Tremblay, M., & Civiero, L. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.07.011 · Cited by 370 · see citing works
McCoy, M. K., Martinez, T. N., Ruhn, K. A., Szymkowski, D. E., Smith, C. G., Botterman, B. R., Tansey, K. E., & Tansey, M. G. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1504-06.2006 · Cited by 355 · see citing works
Beckhauser, T. F., Francis-Oliveira, J., & De Pasquale, R. (2016) · Journal of Experimental Neuroscience · doi:10.4137/jen.s39887 · Cited by 301 · see citing works
Sharifi‐Rad, J., Rodrigues, C. F., Sharopov, F. S., Docea, A. O., Karaça, A. C., Sharifi‐Rad, M., Kahveci, D., Gülseren, G., Şenol, E., Demircan, E., et al. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17072326 · Cited by 295 · see citing works
Self-citationSalehi, B., Sharifi-Rad, J., Cappellini, F., Reiner, Ž., Zorzan, D., Imran, M., Sener, B., Kilic, M., El-Shazly, M., Fahmy, N. M., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01300 · Cited by 293 · see citing works
Self-citationKohutnicka, M., Lewandowska, E., Kurkowska‐Jastrzębska, I., Członkowski, A., & Członkowska, A. (1998) · Immunopharmacology · doi:10.1016/s0162-3109(98)00022-8 · Cited by 283 · see citing works
Impact of Natural Compounds on Neurodegenerative Disorders: From Preclinical to Pharmacotherapeutics
Sharifi‐Rad, M., Lankatillake, C., Dias, D. A., Docea, A. O., Mahomoodally, M. F., Lobine, D., Chazot, P. L., Kurt, B., Tumer, T. B., Moreira, A. C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041061 · Cited by 260 · see citing works
Self-citationGenetic risk factors in Parkinson’s disease
Billingsley, K. J., Bandrés‐Ciga, S., Sáez-Atiénzar, S., & Singleton, A. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2817-y · Cited by 249 · see citing works
The non-motor symptom complex of Parkinson’s disease: A comprehensive assessment is essential
Chaudhuri, К. R., Yates, L. R., & Martínez‐Martín, P. (2005) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-005-0072-6 · Cited by 244 · see citing works
The genetic landscape of Parkinson's disease
Lunati, A., Lesage, S., & Brice, A. (2018) · Revue Neurologique · doi:10.1016/j.neurol.2018.08.004 · Cited by 218 · see citing works
Dopp, J. M., MacKenzie‐Graham, A. J., Otero, G. C., & Merrill, J. E. (1997) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(97)00009-x · Cited by 207 · see citing works
Complex relationship between Parkin mutations and Parkinson disease
West, A. B., Periquet, M., Lincoln, S., Lücking, C. B., Nicholl, D. J., Bonifati, V., Rawal, N., Gasser, T., Lohmann, E., Deleuze, J., et al. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10525 · Cited by 203 · see citing works
Clinical Features of Parkinson’s Disease: The Evolution of Critical Symptoms
Váradi, C. (2020) · Biology · doi:10.3390/biology9050103 · Cited by 196 · see citing works
Neuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K. S. J., & Williams‐Gray, C. H. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01083-5 · Cited by 187 · see citing works
Copas, A. N. M., McComish, S. F., Fletcher, J. M., & Caldwell, M. A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.666737 · Cited by 175 · see citing works
Neuropharmacological Effects of Quercetin: A Literature-Based Review
Islam, M. S., Quispe, C., Hossain, R., Islam, M. T., Al-Harrasi, A., Al-Rawahi, A., Martorell, M., Mamurova, A., Seilkhan, A., Altybaeva, N., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.665031 · Cited by 165 · see citing works
Self-citationZhou, M., Xu, R., Kaelber, D. C., & Gurney, M. E. (2020) · PLOS ONE · doi:10.1371/journal.pone.0229819 · Cited by 157 · see citing works
Lipid-Mediated Oxidative Stress and Inflammation in the Pathogenesis of Parkinson's Disease
Farooqui, T., & Farooqui, A. A. (2011) · Parkinson s Disease · doi:10.4061/2011/247467 · Cited by 155 · see citing works
Evidence of Inflammatory System Involvement in Parkinson’s Disease
Chao, Y., Wong, S. C., & Tan, E. K. (2014) · BioMed Research International · doi:10.1155/2014/308654 · Cited by 150 · see citing works
A Mechanistic and Pathophysiological Approach for Stroke Associated with Drugs of Abuse
Tsatsakis, A. M., Docea, A. O., Călina, D. C., Tsarouhas, K., Zamfira, L.-M., Mitruţ, R., Sharifi‐Rad, J., Kovatsi, L., Siokas, V., Dardiotis, E., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091295 · Cited by 143 · see citing works
Self-citationAstrocytes, Microglia, and Parkinson’s Disease
Joe, E.-H., Choi, D., An, J., Eun, J.-H., Jou, I., & Park, S.-M. (2018) · Experimental Neurobiology · doi:10.5607/en.2018.27.2.77 · Cited by 142 · see citing works
Tibar, H., Bayad, K. E., Bouhouche, A., Haddou, E. H. A. B., Benomar, A., Yahyaoui, M., Benazzouz, A., & Regragui, W. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00170 · Cited by 132 · see citing works
Barnum, C. J., Chen, X., Chung, J., Chang, J., Williams, M., Grigoryan, N., Tesi, R. J., & Tansey, M. G. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-140410 · Cited by 124 · see citing works
Prion-Like Mechanisms in Parkinson’s Disease
Ma, J., Gao, J., Wang, J., & Xie, A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00552 · Cited by 124 · see citing works
Young Onset Parkinson’s Disease: A Modern and Tailored Approach
Post, B., van den Heuvel, L., van Prooije, T. H., van Ruissen, X., van de Warrenburg, B. P. C., & Nonnekes, J. H. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202135 · Cited by 124 · see citing works
Oxidative Stress and Inflammation Interdependence in Multiple Sclerosis
Pădureanu, R., Albu, C. V., Mititelu, R. R., Bacanoiu, M. V., Docea, A. O., Călina, D. C., Pădureanu, V., Olaru, G., Sandu, R. E., Mălin, R. D., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111815 · Cited by 120 · see citing works
Self-citationNonmotor Symptoms in Parkinson’s Disease in 2012: Relevant Clinical Aspects
Bonnet, A. M., Jutras, M., Czernecki, V., Corvol, J., & Vidailhet, M. (2012) · Parkinson s Disease · doi:10.1155/2012/198316 · Cited by 119 · see citing works
McCoy, M. K., Ruhn, K. A., Martinez, T. N., McAlpine, F. E., Blesch, A., & Tansey, M. G. (2008) · Molecular Therapy · doi:10.1038/mt.2008.146 · Cited by 115 · see citing works
Psychiatric aspects of Parkinson’s disease
Grover, S., Somaiya, M. P., Kumar, S., & Avasthi, A. (2014) · Journal of Neurosciences in Rural Practice · doi:10.4103/0976-3147.143197 · Cited by 113 · see citing works
The Effect of Silver Nanoparticles on Antioxidant/Pro-Oxidant Balance in a Murine Model
Docea, A. O., Calina, D., Buga, A. M., Zlatian, O., Paoliello, M. M. B., Mogosanu, G. D., Streba, C. T., Popescu, E. L., Stoica, A. E., Bîrcă, A. C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041233 · Cited by 111 · see citing works
Self-citationInflammatory and Oxidative Stress Markers—Mirror Tools in Rheumatoid Arthritis
Mititelu, R. R., Pădureanu, R., Bacanoiu, M. V., Pădureanu, V., Docea, A. O., Călina, D. C., Bărbulescu, A. L., & Bugă, A. M. (2020) · Biomedicines · doi:10.3390/biomedicines8050125 · Cited by 110 · see citing works
Self-citationTumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease
Nishimura, M., Mizuta, I., Mizuta, E., Yamasaki, S., Ohta, M., Kaji, R., & Kuno, S. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02111-5 · Cited by 95 · see citing works
Epibatidine: A Promising Natural Alkaloid in Health
Salehi, B., Sestito, S., Rapposelli, S., Peron, G., Calina, D., Sharifi-Rad, M., Sharopov, F., Martins, N., & Sharifi-Rad, J. (2018) · Biomolecules · doi:10.3390/biom9010006 · Cited by 91 · see citing works
Self-citationPesticide use and incident Parkinson's disease in a cohort of farmers and their spouses
Shrestha, S., Parks, C. G., Umbach, D. M., Richards-Barber, M., Hofmann, J. N., Chen, H., Blair, A. E., Freeman, L. E. B., & Sandler, D. P. (2020) · Environmental Research · doi:10.1016/j.envres.2020.110186 · Cited by 90 · see citing works
Saravanan, J., & Krishnamurthy, P. T. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105014 · Cited by 89 · see citing works
Moore, A. H., Bigbee, M. J., Boynton, G. E., Wakeham, C. M., Rosenheim, H. M., Staral, C. J., Morrissey, J. L., & Hund, A. K. (2010) · Pharmaceuticals · doi:10.3390/ph3061812 · Cited by 88 · see citing works
Sharifi‐Rad, J., Kamiloğlu, S., Yeskaliyeva, B. K., Beyatlı, A., Alfred, M. A., Salehi, B., Călina, D. C., Docea, A. O., Imran, M., Kumar, N. V. A., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.571459 · Cited by 80 · see citing works
Self-citationWeiss, H. D., & Marsh, L. (2012) · Neurology Clinical Practice · doi:10.1212/cpj.0b013e318278be9b · Cited by 78 · see citing works
Takahashi, M., Suzuki, M., Fukuoka, M., et al. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.14 · Cited by 77 · see citing works
Pathological role of lipid interaction with α-synuclein in Parkinson's disease
Suzuki, M., Sango, K., Wada, K., & Nagai, Y. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.12.014 · Cited by 67 · see citing works
Calina, D., Buga, A. M., Mitroi, M., Buha, A., Caruntu, C., Scheau, C., Bouyahya, A., El Omari, N., El Menyiy, N., & Docea, A. O. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082395 · Cited by 65 · see citing works
Self-citationCalip, G. S., Patel, P. R., Adimadhyam, S., Xing, S., Wu, Z., Sweiss, K. I., Schumock, G. T., Lee, T. A., & Chiu, B. C. ‐. (2018) · International Journal of Cancer · doi:10.1002/ijc.31407 · Cited by 61 · see citing works
Genetics of parkinson's disease
Gasser, T. (1998) · Annals of Neurology · doi:10.1002/ana.410440708 · Cited by 60 · see citing works
A Pharmacological Perspective on Plant-derived Bioactive Molecules for Epilepsy
Sharifi-Rad, J., Quispe, C., Herrera-Bravo, J., Martorell, M., Sharopov, F., Tumer, T. B., Kurt, B., Lankatillake, C., Docea, A. O., Moreira, A. C., et al. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03376-0 · Cited by 60 · see citing works
Self-citationLi, B., Bi, Z., Liu, J., Si, W., Shi, Q., Xue, L., & Bai, J. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12727 · Cited by 58 · see citing works
The understanding of Parkinson's disease through genetics and new therapies
Uwishema, O., Onyeaka, H. N., Badri, R., et al. (2022) · Brain and Behavior · doi:10.1002/brb3.2577 · Cited by 55 · see citing works
Activated microglia facilitate the transmission of α-synuclein in Parkinson's disease
Zheng, T., & Zhang, Z. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105094 · Cited by 53 · see citing works
Parkinson-Associated SNCA Enhancer Variants Revealed by Open Chromatin in Mouse Dopamine Neurons
McClymont, S. A., Hook, P. W., Soto, A. I., Reed, X., Law, W., Kerans, S. J., Waite, E. L., Briceno, N., Thole, J. F., Heckman, M. G., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.10.018 · Cited by 50 · see citing works
Chronic Systemic Inflammation Exacerbates Neurotoxicity in a Parkinson’s Disease Model
Ugalde‐Muñiz, P., Fetter-Pruneda, I., Navarro, L., Garcı́a, E., & Chavarría, A. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/4807179 · Cited by 41 · see citing works
Zhao, Y., & Yang, G. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.104974 · Cited by 40 · see citing works
Tumor Necrosis Factor Inhibition and Parkinson Disease
Kang, X., Ploner, A., Pedersen, N. L., Bandrés‐Ciga, S., Noyce, A. J., Wirdefeldt, K., & Williams, D. M. (2021) · Neurology · doi:10.1212/wnl.0000000000011630 · Cited by 40 · see citing works
Reversal of brain aging by targeting telomerase: A nutraceutical approach
Tsoukalas, D., Buga, A., Docea, A., Sarandi, E., Mitrut, R., Renieri, E., Spandidos, D., Rogoveanu, I., Cercelaru, L., Niculescu, M., et al. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.5032 · Cited by 40 · see citing works
Self-citationSharifi‐Rad, J., Quispe, C., Bouyahya, A., Menyiy, N. E., Omari, N. E., Shahinozzaman, M., Ovey, M. A. H., Koirala, N., Panthi, M., Ertani, A., et al. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6727609 · Cited by 38 · see citing works
Self-citationAntidiabetic Agents for Treatment of Parkinson’s Disease: A Meta-Analysis
Wang, S., Wu, S., Chen, T.-C., & Chuang, C. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17134805 · Cited by 37 · see citing works
Neuroinflammatory responses in Parkinson’s disease: relevance of Ibuprofen in therapeutics
Singh, A. K., Tripathi, P., & Singh, S. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00764-w · Cited by 37 · see citing works
Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson’s Disease
Su, R., & Zhou, T. G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.769506 · Cited by 36 · see citing works
Dopamine Agonists in the Treatment of Parkinsons Disease-Past, Present and Future
Sit, S. Y. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003399581 · Cited by 35 · see citing works
Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
Gundersen, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580311 · Cited by 33 · see citing works
Search for safer and potent natural inhibitors of Parkinson's disease
Khan, S. T., Ahmed, S., Gul, S., Khan, A., & Al‐Harrasi, A. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105135 · Cited by 32 · see citing works
Aloizou, A., Siokas, V., Pateraki, G., Liampas, I., Bakirtzis, C., Tsouris, Z., Lazopoulos, G., Călina, D. C., Docea, A. O., Tsatsakis, A. M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040630 · Cited by 30 · see citing works
Self-citationADORA2A rs5760423 and CYP1A2 rs762551 Polymorphisms as Risk Factors for Parkinson’s Disease
Siokas, V., Aloizou, A.-M., Tsouris, Z., Liampas, I., Liakos, P., Calina, D., Docea, A. O., Tsatsakis, A., Bogdanos, D. P., Hadjigeorgiou, G. M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030381 · Cited by 29 · see citing works
Self-citationNeurobiological Promises of the Bitter Diterpene Lactone Andrographolide
Hossain, R., Quispe, C., Herrera‐Bravo, J., Beltrán, J. F., Islam, M. T., Shaheen, S., Martins, N. A., Martorell, M., Kumar, M., Sharifi‐Rad, J., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3079577 · Cited by 27 · see citing works
Self-citationYeni, Y., Çakır, Z. G., Hacımüftüoğlu, A., Taghizadehghalehjoughi, A., Okkay, U., Genç, S., Yıldırım, S., Sağlam, Y. S., Călina, D. C., Tsatsakis, A. M., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020246 · Cited by 21 · see citing works
Self-citationRelationship between risk and protective factors and clinical features of Parkinson's disease
Belvisi, D., Pellicciari, R., Fabbrini, A., Costanzo, M., Ressa, G., Pietracupa, S., Lucia, M. D., Modugno, N., Magrinelli, F., Dallocchio, C., et al. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.04.017 · Cited by 19 · see citing works
McWilliams, T. G., Howard, L., Wyatt, S. L., et al. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.09.007 · Cited by 15 · see citing works
Role of the Peripheral Nervous System in PD Pathology, Diagnosis, and Treatment
Ma, C., Zhang, W., & Cao, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.598457 · Cited by 15 · see citing works
Non-motor symptoms in Parkinson's disease: An explorative network study
Engels, G., Douw, L., Kerst, Y., et al. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.08.002 · Cited by 13 · see citing works
Konya, C., Hatanaka, Y., Fujiwara, Y., Uchida, K., Nagai, Y., Wada, K., & Kabuta, T. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.05.012 · Cited by 12 · see citing works
Ali, N., Syeda, A., Topgyal, T., et al. (2021) · Current Drug Targets · doi:10.2174/1389450122666210623115505 · Cited by 12 · see citing works
Astrocytes, a Promising Opportunity to Control the Progress of Parkinson’s Disease
Sánchez, A., Moráles, I., Rodriguez‐Sabate, C., Solé-Sabater, M., & Rodrı́guez, M. (2021) · Biomedicines · doi:10.3390/biomedicines9101341 · Cited by 12 · see citing works
Kasahara, J., Choudhury, M. E., Nishikawa, N., Tanabe, A., Tsuji, R., Zhou, Y., Ogawa, M., Yokoyama, H., Tanaka, J., & Nomoto, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00041-3 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Sharifi-Rad, J., Rapposelli, S., Sestito, S., Herrera-Bravo, J., Arancibia-Diaz, A., Salazar, L. A., Yeskaliyeva, B., Beyatli, A., Leyva-Gómez, G., González-Contreras, C., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091515 · Cited by 125 · see citing works
Self-citation
- Authors
- Amin, R., Quispe, C., Docea, A. O., Ydyrys, A., Kulbayeva, M., Durna Daştan, S., Calina, D., & Sharifi-Rad, J.
- Affiliations
- Assam Down Town University (IN)
- Arturo Prat University (CL)
- University of Medicine and Pharmacy of Craiova (RO)
- Al-Farabi Kazakh National University (KZ)
- Venue
- Neurochemistry International
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 158
- Pages
- 105376
- ISSN
- 0197-0186 (ISSN-L)
- OpenAlex
- W4281931196
- Cited by
- 74
- References
- 98
- Citations by year
- 2026: 18 · 2025: 18 · 2024: 19 · 2023: 11 · 2022: 8
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Neurochemistry International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- TNF-α, neuroinflammation, Parkinson's disease, glial cells, cytokines, PPARγ agonists, neuroprotection, neurotoxicity
- MeSH terms
- Neuroinflammatory Diseases, Humans, Inflammation, Parkinson Disease, Tumor Necrosis Factor-alpha, Microglia, Neurodegenerative Diseases, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
